Press Releases

Interleukin Genetics Cites Role in Key Antisense Drug Trial Published in The Lancet

Interleukin’s Genetic Test Patterns Provide Key Genetic Data in Clinical Studies

WALTHAM, Mass., September 22, 2016 — Interleukin Genetics, Inc. (OTCQB: ILIU) a life science company focused on the genetics of chronic inflammation, today announced their contribution to the key publication in The Lancet (September 21, 2016) of the article “Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomized, double blind, placebo-controlled, dose ranging trials.” The article provides strong evidence that the antisense drug IONIS-APO(a)-LRX is well tolerated and capable of achieving substantial reductions in Lp(a) concentrations in patients. The drug is intended, in part, to reduce the risk for secondary cardiovascular events in individuals with elevated Lp(a).

“This prestigious publication shows the potential for Interleukin-1 genetic variations […]

Interleukin-1 Genetic Variations Influence Obesity Effect in Periodontal Disease Progression

Interleukin Genetics Provides New Evidence for Role of IL-1 Genetic Variations in Determining Impact of Obesity on Chronic Inflammatory Diseases

Waltham, Mass (August 23, 2016) – Interleukin Genetics, Inc. (OTCQB: ILIU) a life science company focused on the genetics of chronic inflammation, today announced the publication of the article “Influence of Obesity on Periodontitis Progression is Conditional on IL-1 Inflammatory Genetic Variation” in the Journal of Periodontology (http://www.joponline.org/doi/abs/10.1902/jop.2016.160408 ).The article is the result of a scientific collaboration with key researchers at Boston University and strongly supports the value of Interleukin-1 (IL-1) genetics in amplifying the negative impact of obesity.

“Interleukin Genetics continues to build scientific support for the clinical value of IL-1 genetic information,” said Ken Kornman, Chief Scientific Officer. […]

Interleukin Genetics Reports Second Quarter 2016 Financial Results

WALTHAM, Mass. – August 16, 2016 – Interleukin Genetics, Inc. (OTCQB: ILIU) today announced financial results for its fiscal second quarter of 2016, ended June 30, 2016, and provided a corporate update.

“The second quarter was significant for Interleukin Genetics, as we continue to advance our commercial plan to drive market adoption of PerioPredict®, our genetic test that identifies individuals with an increased risk for severe and progressive periodontitis due to a life-long genetic predisposition to over-produce Interleukin-1 (IL-1), a key mediator of inflammation,” said Mark B. Carbeau, Chief Executive Officer of Interleukin Genetics.  “Since the beginning of the year, we’ve made progress on both tracks of our commercial strategy, signing new licensing agreements for PerioPredict with both a large self-insured […]

Interleukin Genetics Announces Conference Call to Discuss Second Quarter 2016 Financial Results

WALTHAM, MA – August 9, 2016 – Interleukin Genetics, Inc. (OTCQB: ILIU) announced today that it will host a conference call and webcast on Tuesday, August 16, 2016, at 8:30 a.m. Eastern Time to provide a corporate update and discuss the Company’s financial results for the second quarter ended June 30, 2016.

Tuesday, August 16th, 8:30 a.m. Eastern Time

Dial in (domestic):                 877-324-1976
Dial in (international):            631-291-4550
Conference ID:                       62562552

A live webcast will also be available at the Investors section of the Company’s website at www.ilgenetics.com.  The webcast will be archived following the call at www.ilgenetics.com.

About Interleukin Genetics

Interleukin Genetics, Inc. (OTCQB: ILIU) […]

Interleukin Genetics Strengthens Commercial Leadership with Key Appointments

Stephan Toutain appointed Chief Commercial Officer and Mary Hiter appointed Director of Marketing

WALTHAM, Mass. – August 3, 2016 – Interleukin Genetics, Inc. (OTCQB: ILIU), a life science company focused on the genetics of chronic inflammation, today announced the appointment of two senior leaders to enhance its commercial team and capabilities. Stephan Toutain will join Interleukin as Chief Commercial Officer, and Mary Hiter will become Director of Marketing, both newly created roles at the company. Mr. Toutain and Ms. Hiter will join Interleukin later this month.

“These appointments are an important step in our strategy to drive the market adoption of our PerioPredict® Genetic Risk Test and Patient Engagement Platform. Stephan is a seasoned business leader and an experienced sales and marketing executive who […]

Interleukin Genetics, Inc. Announces $5.6 Million Private Placement Financing

WALTHAM, MA – August 1, 2016 – Interleukin Genetics, Inc. (OTCQB:  ILIU), a life sciences company focused on developing and marketing proprietary genetic tests for chronic diseases and health-related conditions, announced today that it has entered into an agreement with various accredited and institutional investors to raise gross proceeds of approximately $5.6 million in a private placement financing. The syndicate is composed of existing investors, including two leading life sciences investment firms, Bay City Capital and New Enterprise Associates (NEA), and Pyxis Innovations Inc., an affiliate of Alticor Inc. (parent company to Amway Corporation), and broad participation among the management team.

The investment in Interleukin Genetics consists of the sale and issuance of 56,262,571 shares of common stock at a price […]

Interleukin Genetics To Offer Its Innovative Inflammation Management Program To Amway Employees

Interleukin Genetics To Provide Integrated Program of Genetic Risk Assessment and Patient Engagement To Support Better Health

 

WALTHAM, MA – July 12, 2016 – Interleukin Genetics, Inc. (OTCQB: ILIU), a life sciences company focused on the genetics of chronic inflammation announced today that it has signed an agreement with Amway, a leading direct selling company, to provide Interleukin’s PerioPredict® Genetic Risk Test and Patient Engagement Platform to Amway’s employees as part of an enhanced employee benefits plan. Under terms of the agreement, Interleukin Genetics will make PerioPredict available to Amway’s approximately 5,000 employees in the US. The program is expected to begin in September 2016.

PerioPredict identifies individuals at increased risk for severe periodontitis due to a genetic tendency to […]

Interleukin Genetics Reports First Quarter 2016 Financial Results

Two Agreements Year to Date to Incorporate PerioPredict® into Employee Benefit Plans

Conference call today at 8:30 AM Eastern Standard time
WALTHAM, Mass. – May 16, 2016 – Interleukin Genetics, Inc. (OTCQB: ILIU) today announced financial and operational results for its fiscal first quarter of 2016, ended March 31, 2016.

“Our focus at Interleukin Genetics over the past year has been on developing a commercial plan that will drive market adoption of PerioPredict®, our genetic test that identifies individuals with an increased risk for severe and progressive periodontitis due to a life-long genetic predisposition to over-produce Interleukin-1 (IL-1), a key mediator of inflammation. Elevated inflammation is implicated in numerous chronic diseases,” said Mark B. Carbeau, Chief Executive Officer of Interleukin Genetics.

“Our enhanced […]

Interleukin Genetics Announces Conference Call to Discuss First Quarter 2016 Financial Results

WALTHAM, MA – May 10, 2016 – Interleukin Genetics, Inc. (OTCQB: ILIU) announced today that it will host a conference call and webcast on Monday, May 16, 2016, at 8:30 a.m. Eastern Time to provide a corporate update and discuss the Company’s first quarter ended March 31, 2016 financial results.

Monday, May 16th, 8:30 a.m. Eastern Time

Dial in (domestic):                  877-324-1976
Dial in (international):            631-291-4550
Conference ID:                      5524079

A live webcast will also be available at the Investors section of the Company’s website at www.ilgenetics.com.  The webcast will be archived following the call at www.ilgenetics.com.

About Interleukin Genetics

Interleukin Genetics, Inc. (OTCQB: ILIU) develops and markets […]

Genetic Stratification of Drug Response in IL-1 Implicated Eye Diseases

Interleukin Genetics Utilizes Genetic Patterns in Investigational Drug Response Evaluation

WALTHAM, MA – May 4, 2016 – Interleukin Genetics, Inc. (OTCQB: ILIU), a life sciences company focused on developing and marketing proprietary genetic tests for chronic diseases and health-related conditions, announced today that Eleven Biotherapeutics, Inc. (NASDAQ: EBIO), a biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, presented new data from post hoc analyses on the influence of Interleukin’s IL-1 genetic patterns on response to isunakinra (EBI-005) in severe allergic conjunctivitis and severe dry eye study subjects.  The data were presented at the Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO) in Seattle, Washington.

“Working with Eleven Biotherapeutics to […]